Edition:
United Kingdom

Nuvectra Corp (NVTR.OQ)

NVTR.OQ on NASDAQ Stock Exchange Global Market

9.00USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$9.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
13,668
52-wk High
$14.55
52-wk Low
$4.94

Chart for

About

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food... (more)

Overall

Beta: --
Market Cap(Mil.): $143.81
Shares Outstanding(Mil.): 10.70
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Nuvectra reports Q3 loss per share $1.09

* Q3 revenue rose 102 percent to $7.6 million Source text for Eikon: Further company coverage:

01 Nov 2017

BRIEF-Nuvectra corp files for mixed shelf of upto $100 mln

* Nuvectra Corp files for mixed shelf of upto $100 million - sec filing‍​ Source text : http://bit.ly/2hQeDbP Further company coverage:

05 Oct 2017

BRIEF-Nuvectra corp says effective Aug. 31, co entered into amended and restated development agreement with Aleva Neurotherapeutics - SEC filing

* Nuvectra Corp - effective august 31, co entered into amended and restated development agreement with Aleva Neurotherapeutics, S.A - SEC filing

05 Sep 2017

BRIEF-Nuvectra Q2 loss per share $1.07

* Q2 revenue rose 183 percent to $7.2 million Source text for Eikon: Further company coverage:

08 Aug 2017

BRIEF-Nuvectra unit enters into business property lease agreement

* Nuvectra Corp - effective July 1, 2017, unit entered into a business property lease agreement with BMT Ann Arbor, Llc Source text: (http://bit.ly/2u7IQEO) Further company coverage:

30 Jun 2017

BRIEF-Nuvectra enters second amendment to development agreement with Aleva Neurotherapeutics

* Nuvectra- effective june 19, co entered second amendment to development agreement with aleva neurotherapeutics, s.a to amend agreement dated jan 29, 2016

21 Jun 2017

BRIEF-Nuvectra files regulatory submission with FDA for Algovita MRI-conditional approval

* Nuvectra files regulatory submission with fda for Algovita MRI-conditional approval

21 Jun 2017

Earnings vs. Estimates